Do you gain weight when you stop Wegovy?

Step 1: the biology kicks back in almost immediately

Semaglutide has a half-life of roughly a week, meaning concentrations fall sharply once you stop injecting. Within two to four weeks, GLP-1 receptor activity returns to baseline. The practical result is a fairly rapid return of appetite: food feels less filling, meal satisfaction drops, and cravings that were suppressed during treatment tend to resurface. This is not unique to Wegovy. It reflects a well-documented property of GLP-1 medicines: their effects are present only while the drug is active.

What makes this harder than ordinary dieting is the body's weight-defence mechanisms. After significant weight loss, the brain adjusts hunger hormones like ghrelin upward and reduces the metabolic rate to below what you would expect for your new size. These adaptations persist after stopping treatment. So appetite returns while the body simultaneously burns fewer calories than expected. The two pressures combine to make regain rapid.

For a fuller picture of what drives the scales in the other direction, the causes of weight gain during Wegovy treatment overlap with what can happen on stopping, and the mechanisms are worth understanding in that context too.

Step 2: understanding the scale of regain the evidence shows

The STEP 1 extension trial followed adults who completed 68 weeks of treatment. In the year after stopping, participants regained on average around 11–12 percentage points of body weight, bringing total net loss down to roughly 5–6% compared to their starting weight. By one year post-treatment, much of the cardiometabolic improvement, including blood pressure, cholesterol, and blood-glucose markers, had also partially reversed.

These figures apply to abrupt discontinuation without any structured support. They are the ceiling of the regain risk, not an inevitable outcome for everyone. Factors that influence how quickly and how much weight returns include the duration of treatment, the degree of lifestyle change maintained, muscle mass preserved during treatment, and any underlying metabolic conditions.

If you stopped losing weight before discontinuing, that is a separate but related question, and understanding the plateau itself matters. Our page on what to do when weight loss stalls on Wegovy covers that scenario in detail.

Step 3: what actually reduces the risk of regain after stopping

The most robust evidence-based option is continuing treatment. NICE's recommendation for semaglutide (TA875) notes that ongoing treatment is associated with continued weight maintenance, and that stopping is associated with return of weight. Where a prescriber judges it clinically appropriate, ongoing low-dose maintenance is an option that can be discussed.

For people who do stop, the evidence points to a few practical priorities. Protein intake matters: preserving muscle during treatment means the metabolic rate is better protected, and continuing adequate protein after stopping slows the rate of fat regain even when total weight begins to rise. Structured physical activity, particularly resistance training, has a similar protective effect on lean mass. Consistent meal timing and portion habits formed during treatment provide some buffer, though they cannot fully compensate for the return of biological hunger.

Our page on how to stop Wegovy without gaining weight sets out these steps in practical terms, including how to plan the transition with your prescriber. There is also a cost dimension worth considering honestly: the cost of Wegovy treatment is a real factor in whether people continue, pause, or stop, and understanding what's included in a private prescription service matters when making that decision.

Step 4: if you're thinking about restarting

People who regain weight after stopping Wegovy can restart treatment, subject to a fresh clinical assessment. There is no evidence that restarting is less effective than the first course, though the titration schedule restarts from the beginning to allow the body to readjust. A prescriber will review your current weight, any changes in your health since stopping, and whether the same medicine remains the right fit.

Semaglutide is one of two GLP-1 medicines licensed for weight management in the UK; if you are weighing up options, the broader semaglutide overview and the Wegovy treatment page cover how the medicine works and what the licensed programme looks like. The question of timing, specifically when weight loss typically begins after restarting, is addressed on our page about when you start losing weight on Wegovy.

These are prescription-only medicines. Suitability for restarting, changing dose, or switching is decided by a prescriber based on your individual circumstances, not by a general rule. If you're considering next steps, a clinical conversation is the right starting point. Our prescribers review consultations the same day, and once approved, treatment is dispensed from our GPhC-registered pharmacy and delivered by DPD the next working day, tracked to your door in plain, unbranded packaging.

You can verify our pharmacy on the GPhC register at registration number 9012878.